Glenmark Life Sciences IPO: The company has debt-to-equity of 1.3x with a debt of Rs 916 crore which includes Rs 800 crore payable to Glenmark Pharmaceuticals, post-IPO debt will be negligible. Read More
reported by at Moneycontrol
Recent Posts
- JPMorgan downgrades Indian IT sector but bullish on these 4 IT stocks | Mint – Mint
- PhysicsWallah raises $100 million from Westbridge, GSV Ventures, joins unicorn club – Moneycontrol
- Gold loan platform Rupeek lays off over 180 of its employees – Moneycontrol
- JPMorgan Sees 60% Upside In Paytm’s Beaten-Down Stock. Here’s Why… – BQ Prime
- Policybazaar tanks 10% as CEO Yashish Dahiya plans 3.77 mn share sale – Business Standard
Archives
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
Recent Comments